Adamas Pharmaceuticals focuses on a portfolio of therapies to reduce the burden of neurological diseases on patients, caregivers, and society. Co.'s portfolio includes: GOCOVRI® (amantadine) extended release capsules for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as adjunctive treatment for patients with Parkinson's disease taking levodopa/carbidopa experiencing reemergence or sudden return of stiffness, rigidity and tremors; and OSMOLEX ER® (amantadine) extended release tablets for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. We show 31 historical shares outstanding datapoints in our ADMS shares outstanding history coverage, used to compute ADMS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ADMS market cap history over the course of time is important for investors
interested in comparing ADMS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ADMS versus a peer is one thing; comparing
ADMS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ADMS can fluctuate over the course of history.
With this page we aim to empower investors researching ADMS by allowing them to research the ADMS market cap history. |
Free ADMS Email Alerts:
Video: The Importance of Market Cap
